2009-2010

This page in English

2010

EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs.
Bertsias G, Ioannidis J, Aringer M, Bollen E, Bombardieri S, Bruce I, et al
Ann. Rheum. Dis. 2010 Dec;69(12):2074-82

Patient-reported 28 swollen and tender joint counts accurately represent RA disease activity and can be used to assess therapy responses at the group level.
Riazzoli J, Nilsson J, Teleman A, Petersson I, Rantapää-Dahlqvist S, Jacobsson L, et al
Rheumatology (Oxford) 2010 Nov;49(11):2098-103

Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus.
Urowitz M, Gladman D, Ibañez D, Bae S, Sanchez-Guerrero J, Gordon C, et al
Arthritis Care Res (Hoboken) 2010 Jun;62(6):881-7

Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA.
Nam J, Winthrop K, van Vollenhoven R, Pavelka K, Valesini G, Hensor E, et al
Ann. Rheum. Dis. 2010 Jun;69(6):976-86

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.
Smolen J, Landewé R, Breedveld F, Dougados M, Emery P, Gaujoux-Viala C, et al
Ann. Rheum. Dis. 2010 Jun;69(6):964-75

Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts.
Jónsdóttir T, Gunnarsson I, Mourão A, Lu T, van Vollenhoven R, Isenberg D
Rheumatology (Oxford) 2010 Aug;49(8):1502-4

New and future agents in the treatment of rheumatoid arthritis.
van Vollenhoven R
Discov Med 2010 Apr;9(47):319-27

Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus.
Nossent J, Kiss E, Rozman B, Pokorny G, Vlachoyiannopoulos P, Olesinska M, et al
Lupus 2010 Jul;19(8):949-56

Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study.
van Vollenhoven R, Cifaldi M, Ray S, Chen N, Weisman M
Arthritis Care Res (Hoboken) 2010 Feb;62(2):226-34

Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study.
van Vollenhoven R, Cifaldi M, Ray S, Chen N, Weisman M
Arthritis Care Res (Hoboken) 2010 Feb;62(2):226-34

The selective estrogen receptor alpha agonist Org 37663 induces estrogenic effects but lacks antirheumatic activity: a phase IIa trial investigating efficacy and safety of Org 37663 in postmenopausal female rheumatoid arthritis patients receiving stable background methotrexate or sulfasalazine.
van Vollenhoven R, Houbiers J, Buttgereit F, In 't Hout J, Boers M, Leij S, et al
Arthritis Rheum. 2010 Feb;62(2):351-8

Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials.
van Vollenhoven R, Emery P, Bingham C, Keystone E, Fleischmann R, Furst D, et al
J. Rheumatol. 2010 Mar;37(3):558-67

Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden.
Lekander I, Borgström F, Svarvar P, Ljung T, Carli C, van Vollenhoven R
Int J Technol Assess Health Care 2010 Jan;26(1):54-61

European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies.
Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, Brey R, et al
Ann. Rheum. Dis. 2010 Jul;69(7):1269-74

Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions.
Van den Bosch F, Manger B, Goupille P, McHugh N, Rødevand E, Holck P, et al
Ann. Rheum. Dis. 2010 Feb;69(2):394-9

Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry).
Augustsson J, Neovius M, Cullinane-Carli C, Eksborg S, van Vollenhoven R
Ann. Rheum. Dis. 2010 Jan;69(1):126-31

Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus.
Hanly J, Urowitz M, Su L, Bae S, Gordon C, Wallace D, et al
Ann. Rheum. Dis. 2010 Mar;69(3):529-35

Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial.
Strand V, Mease P, Burmester G, Nikaï E, Coteur G, van Vollenhoven R, et al
Arthritis Res. Ther. 2009 ;11(6):R170

European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies.
Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, Brey R, et al
Ann. Rheum. Dis. 2010 Jul;69(7):1269-74

2009

Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis.
Kavanaugh A, Smolen J, Emery P, Purcaru O, Keystone E, Richard L, et al
Arthritis Rheum. 2009 Nov;61(11):1592-600

Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
Askling J, van Vollenhoven R, Granath F, Raaschou P, Fored C, Baecklund E, et al
Arthritis Rheum. 2009 Nov;60(11):3180-9

Treatment of rheumatoid arthritis: state of the art 2009.
van Vollenhoven R
Nat Rev Rheumatol 2009 Oct;5(10):531-41

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial.
van Vollenhoven R, Ernestam S, Geborek P, Petersson I, Cöster L, Waltbrand E, et al
Lancet 2009 Aug;374(9688):459-66

How to dose infliximab in rheumatoid arthritis: new data on a serious issue.
van Vollenhoven R
Ann. Rheum. Dis. 2009 Aug;68(8):1237-9

Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis.
Hueber W, Tomooka B, Batliwalla F, Li W, Monach P, Tibshirani R, et al
Arthritis Res. Ther. 2009 ;11(3):R76

Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis.
Emery P, Genovese M, van Vollenhoven R, Sharp J, Patra K, Sasso E
J. Rheumatol. 2009 Jul;36(7):1429-41

Sex differences in rheumatoid arthritis: more than meets the eye...
van Vollenhoven R
BMC Med 2009 Mar;7():12

Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe.
Emery P, Van Vollenhoven R, Ostergaard M, Choy E, Combe B, Graninger W, et al
Ann. Rheum. Dis. 2009 Apr;68(4):456-9

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial.
Smolen J, Landewé R, Mease P, Brzezicki J, Mason D, Luijtens K, et al
Ann. Rheum. Dis. 2009 Jun;68(6):797-804

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study.
Fleischmann R, Vencovsky J, van Vollenhoven R, Borenstein D, Box J, Coteur G, et al
Ann. Rheum. Dis. 2009 Jun;68(6):805-11

Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register.
Askling J, Baecklund E, Granath F, Geborek P, Fored M, Backlin C, et al
Ann. Rheum. Dis. 2009 May;68(5):648-53

EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpoints.
Bertsias G, Ioannidis J, Boletis J, Bombardieri S, Cervera R, Dostal C, et al
Ann. Rheum. Dis. 2009 Apr;68(4):477-83

EULAR points to consider for conducting clinical trials in systemic lupus erythematosus.
Gordon C, Bertsias G, Ioannidis J, Boletis J, Bombardieri S, Cervera R, et al
Ann. Rheum. Dis. 2009 Apr;68(4):470-6

InflammationReumatologi